Australia - English - Department of Health (Therapeutic Goods Administration)

actavis pty ltd - tamoxifen citrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

ad management services pty ltd t/a the natural way - aesculus hippocastanum,allium sativum,dl-alpha tocopheryl acetate,ginkgo biloba,rutin -

Australia - English - Department of Health (Therapeutic Goods Administration)

natural bio pty limited - allium sativum,althaea officinalis,armoracia rusticana,ascorbic acid,trigonella foenum-graecum -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - spironolactone, quantity: 100 mg - tablet, film coated - excipient ingredients: macrogol 400; maize starch; hypromellose; calcium sulfate dihydrate; povidone; magnesium stearate; titanium dioxide; purified water; iron oxide yellow; iron oxide red; industrial methylated spirit; flavour - essential hypertension; oedematous disorders such as oedema and ascites of congestive cardiac failure, cirrhosis of the liver, nephrotic syndrome; diagnosis and treatment of primary hyperaldosteronism; as adjunctive therapy in malignant hypertension; in diuretic induced hypokalaemia when other measures are considered inappropriate or inadequate; prophylaxis of hypokalaemia in patients taking digitalis when other measures are considered inadequate or inappropriate, hirsutism. essential hypertension: aldactone, when used alone, is effective in lowering both systolic and diastolic blood pressure. aldactone improves the hypotensive action of thiazide diuretics while at the same time reducing or preventing potassium loss due to the thiazide. aldactone enhances the effectiveness of other antihypertensive agents such as beta blockers, vasodilators etc. congestive cardiac failure: aldactone, when used alone, is effective in the management of oedema and sodium retention associated with congestive cardiac failure. aldactone may be used in combination with a thiazide or other conventional diuretics for achieving diuresis in patients whose oedema is resistant to a thiazide or other conventional diuretics. unlike conventional diuretics aldactone does not produce hypokalaemia. when administered with a thiazide or other conventional diuretics aldactone offsets hypokalaemia induced by these diuretics. the prevention of potassium loss is particularly important in the treatment of digitalized patients since digitalis intoxication may be precipitated if hypokalaemia is induced by conventional diuretic therapy. hepatic cirrhosis with ascites and oedema: aldactone when used alone is frequently adequate for the relief of ascites and oedema associated with hepatic cirrhosis. aldactone provides a mild and even diuresis and prevents excessive potassium excretion caused by thiazide diuretics thus avoiding possible precipitation of hepatic coma. nephrotic syndrome : although glucocorticoids, whose anti inflammatory activity appears to benefit the primary pathologic process in the renal glomerulus, should probably be employed first, aldactone either alone or in combination with a conventional diuretic is useful for inducing diuresis. primary hyperaldosteronism: aldactone may be used to establish the diagnosis of primary hyperaldosteronism by therapeutic trial. aldactone may also be used for the short term pre operative treatment of patients with primary hyperaldosteronism, long term maintenance therapy for patients with discrete aldosterone producing adrenal adenomas who are judged to be poor operative risks (or who decline surgery), and the long term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). hirsutism in females: aldactone is effective in the treatment of females with hirsutism, an androgen related increase in facial and body hair. a reduction in hair growth, hair shaft diameter and hair pigmentation is seen. use of aldactone should be considered only after all other alternatives of non drug therapy have been explored. for women of child bearing age, see contraindications and precautions, use in pregnancy.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - spironolactone, quantity: 25 mg - tablet, film coated - excipient ingredients: macrogol 400; hypromellose; maize starch; calcium sulfate dihydrate; magnesium stearate; povidone; flavour; titanium dioxide; purified water; iron oxide yellow; iron oxide red; industrial methylated spirit - essential hypertension; oedematous disorders such as oedema and ascites of congestive cardiac failure, cirrhosis of the liver, nephrotic syndrome; diagnosis and treatment of primary hyperaldosteronism; as adjunctive therapy in malignant hypertension; in diuretic induced hypokalaemia when other measures are considered inappropriate or inadequate; prophylaxis of hypokalaemia in patients taking digitalis when other measures are considered inadequate or inappropriate, hirsutism. essential hypertension: aldactone, when used alone, is effective in lowering both systolic and diastolic blood pressure. aldactone improves the hypotensive action of thiazide diuretics while at the same time reducing or preventing potassium loss due to the thiazide. aldactone enhances the effectiveness of other antihypertensive agents such as beta blockers, vasodilators etc. congestive cardiac failure: aldactone, when used alone, is effective in the management of oedema and sodium retention associated with congestive cardiac failure. aldactone may be used in combination with a thiazide or other conventional diuretics for achieving diuresis in patients whose oedema is resistant to a thiazide or other conventional diuretics. unlike conventional diuretics aldactone does not produce hypokalaemia. when administered with a thiazide or other conventional diuretics aldactone offsets hypokalaemia induced by these diuretics. the prevention of potassium loss is particularly important in the treatment of digitalized patients since digitalis intoxication may be precipitated if hypokalaemia is induced by conventional diuretic therapy. hepatic cirrhosis with ascites and oedema: aldactone when used alone is frequently adequate for the relief of ascites and oedema associated with hepatic cirrhosis. aldactone provides a mild and even diuresis and prevents excessive potassium excretion caused by thiazide diuretics thus avoiding possible precipitation of hepatic coma. nephrotic syndrome : although glucocorticoids, whose anti inflammatory activity appears to benefit the primary pathologic process in the renal glomerulus, should probably be employed first, aldactone either alone or in combination with a conventional diuretic is useful for inducing diuresis. primary hyperaldosteronism: aldactone may be used to establish the diagnosis of primary hyperaldosteronism by therapeutic trial. aldactone may also be used for the short term pre operative treatment of patients with primary hyperaldosteronism, long term maintenance therapy for patients with discrete aldosterone producing adrenal adenomas who are judged to be poor operative risks (or who decline surgery), and the long term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). hirsutism in females: aldactone is effective in the treatment of females with hirsutism, an androgen related increase in facial and body hair. a reduction in hair growth, hair shaft diameter and hair pigmentation is seen. use of aldactone should be considered only after all other alternatives of non drug therapy have been explored. for women of child bearing age, see contraindications and precautions, use in pregnancy.

Australia - English - Department of Health (Therapeutic Goods Administration)

landauer radiopharmaceuticals pty ltd - gallium (67ga) citrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

landauer radiopharmaceuticals pty ltd - gallium (67ga) citrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

landauer radiopharmaceuticals pty ltd - gallium (67ga) citrate -

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - flutamide 250mg;   - tablet - 250 mg - active: flutamide 250mg   excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch microcrystalline cellulose pregelatinised maize starch purified water sodium laurilsulfate - for the palliative treatment of advanced prostatic cancer in previously untreated patients or those who have not responded or who have become refractory to hormonal manipulation. as a component of the treatment used in the management of locally advanced prostatic carcinoma.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - tamoxifen citrate 15.2mg equivalent to tamoxifen 10 mg;   - tablet - 10 mg - active: tamoxifen citrate 15.2mg equivalent to tamoxifen 10 mg   excipient: croscarmellose sodium magnesium stearate maize starch mannitol - indicated for the treatment of breast cancer